You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.
The improvement in the 360Dx Index was modest compared to 2017, but it still outpaced the broader markets, which fell dramatically in the last month of the year.
November's modest gain followed a tough October, when the index down almost 9 percent. Meridian Bio paced the gainers, and NantHealth was the steepest decliner.
Walgreens, Laboratory Corporation of America, and Inland Empire Health Plan (IEHP) this week announced plans to open nine new LabCorp patient centers within Walgreens stores in the greater Riverside, California area.
The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.
The firm announced in October that had entered into an agreement with Jefferies to sell up to $50 million in shares from time to time.
The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.
The company said it intends to use the proceeds for working capital and corporate purposes, including capital expenditures, R&D, clinical trials, and more.
The stock prices for 14 companies in the 360Dx Index were down during the month, while 13 firms' share prices fell.